Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients

Metabolism: Clinical and Experimental

Volumn 58, Issue 3, 2009, Pages 421-425

  Nakamura, Kazuo ^a,b   Adachi, Hisashi ^a   Matsui, Takanori ^a   Kurita, Yayoi ^b   Takeuchi, Masayoshi ^c   Yamagishi, Sho ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Nakamura Clinic   (Japan)

^c HOKURIKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALANINE AMINOTRANSFERASE; BRAIN NATRIURETIC PEPTIDE; GAMMA GLUTAMYLTRANSFERASE; HIGH MOBILITY GROUP B1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CREATININE CLEARANCE; ESSENTIAL HYPERTENSION; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE;

AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BLOOD PRESSURE; CREATININE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LIPIDS; MALE; PATIENT SELECTION; RECEPTORS, IMMUNOLOGIC;

EID: 59649124763     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.10.020     Document Type: Article

References (35)

1. Vlassara H., Bucala R., and Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab invest 70 (1994) 138-150
2. Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann Rev Med 46 (1995) 223-234
3. Dyer D.G., Blackledge J.A., Thorpe S.R., and Baynes J.W. Formation of pentosidine during nonenzymatic browning of proteins by glucose. J Biol Chem 18 (1991) 11654-11660
4. Grandhee S., and Monnier V.M. Mechanism of formation of the Maillard protein cross-link pentosidine. J Biol Chem 18 (1991) 11649-11653
5. Schmidt A.M., and Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 5 (2000) 430-436
6. ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272 (1997) 17810-17814
7. Yamagishi S., and Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11 (2005) 2279-2299
8. Jandeleit-Dahm K., and Cooper M.E. The role of AGEs in cardiovascular disease. Curr Pharm Des 14 (2008) 979-986
9. Park L., Raman K.G., Lee K.J., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat Med 4 (1998) 1025-1031
10. Bucciarelli L., Wendt T., Qu W., et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106 (2002) 2827-2835
11. Rauvala H., and Pihlaskari R. Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J Biol Chem 262 (1987) 16625-16635
12. Andersson U., Erlandsson-Harris H., Yang H., and Tracey K.J. HMGB1 as a DNA-binding cytokine. J Leukoc Biol 72 (2002) 1084-1091
13. Czura C.J., Wang H., and Tracey K.J. Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res 7 (2001) 315-321
14. Klune J.R., Dhupar R., Cardinal J., Billiar T.R., and Tsung A. HMGB1: endogenous danger signaling. Mol Med 14 (2008) 476-484
15. Hudson B.I., Harja E., Moser B., and Schmidt A.M. Soluble levels of receptor for advanced glycation end products (sRAGE) and coronary artery disease. The next C-reactive protein?. Arterioscler Thromb Vasc Biol 25 (2005) 879-882
16. Yamagishi S., Matsui T., and Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets 8 (2007) 1138-1143
17. Yamagishi S., Adachi H., and Nakamura K. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 55 (2006) 1227-1231
18. Nakamura K., Yamagishi S., Matsui T., et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin Exp Med 7 (2007) 188-190
19. Tan K.C., Shiu S.W., Chow W.S., et al. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 49 (2006) 2756-2762
20. Nakamura K., Yamagishi S., Adachi H., et al. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev 24 (2008) 109-114
21. Nakamura K., Yamagishi S., Adachi H., et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 13 (2007) 185-189
22. Nakamura K., Yamagishi S., Adachi H., et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 23 (2007) 368-371
23. Tanaka N., Yonekura H., Yamagishi S., et al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 275 (2000) 25781-25790
24. Yamagishi S., and Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGE expression in diabetes. Arterioscler Thromb Vasc Biol 27 (2007) e32
25. Takeuchi M., Makita Z., Bucala R., et al. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 6 (2000) 114-125
26. Humpert P.M., Djuric Z., Kopf S., et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 6 (2007) 9
27. Kislinger T., Fu C., Huber B., et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274 (1999) 31740-31749
28. Rashid G., Benchetrit S., Fishman D., and Bernheim J. Effect of advanced glycation end-products on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells. Kidney Int 66 (2004) 1099-1106
29. Fiuza C., Bustin M., Talwar S., et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101 (2003) 2652-2660
30. Kalousová M., Hodková M., Kazderová M., et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 47 (2006) 406-411
31. Unoki H., Bujo H., Yamagishi S., et al. Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. Diabetes Res Clin Pract 76 (2006) 236-244
32. Garcia-Macedo R., Sanchez-Muñoz F., Almanza-Perez J.C., Duran-Reyes G., Alarcon-Aguilar F., and Cruz M. Glycine increases mRNA adiponectin and diminishes pro-inflammatory adipokines expression in 3T3-L1 cells. Eur J Pharmacol 587 (2008) 317-321
33. Hyogo H., and Yamagishi S. Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des 14 (2008) 969-972
34. Cataldegirmen G., Zeng S., Feirt N., et al. RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med 201 (2005) 473-484
35. Geroldi D., Falcone C., Emanuele E., et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 23 (2005) 1725-1729